Effectiveness of a collaborative care intervention between pharmacies and primary care targeting hypertension and hyperlipidemia

Effectiveness of a collaborative care intervention between pharmacies and primary care targeting hypertension and hyperlipidemia: a multi-centre quasi-experimental controlled trial (USFarmácia)

Registry ID
ISRCTN13410498
Source registry
ISRCTN
Status
No longer recruiting
Study type
INTERVENTIONAL
Sponsor
Associação Nacional das Farmácias
Enrollment
688
Start date
2018-04-27
Completion date
2019-07-31
Last update
2026-08-17

Conditions

Summary

Hypertension and/or hyperlipidemia

Detailed description

This is a 6 month multi-center, pragmatic, quasi-experimental controlled trial involving community pharmacies and primary care in Portugal. A primary care unit has expressed interest in this collaborative care model and has become the pilot site. Intervention pharmacies have been selected as per selection criteria. Control primary care units with similar patient populations have been identified and pharmacies in geographic proximity are invited to collect data on control patients. The trialists aim at recruiting patients with an allocation ratio of 1:1 in intervention and control arm. All patients are recruited in pharmacies. It will not be possible for intervention providers and patients to be blinded to which group due to the nature of the collaborative intervention. 1. Intervention: Hypertension and/or hyperlipidemia management in collaborative care by pharmacies and primary care according to pre-defined care protocols. Collaborative intervention package consists of the following components: 1.1. Point-of-care measurements at pharmacy/USF 1.2. Cardiovascular risk assessment at pharmacy/USF 1.3. Medication management at pharmacy/USF 1.4. Lifestyle counselling at pharmacy/USF 1.5. Referral and direct request for medical appointment from pharmacy to USF via IT, as per care protocol 1.6. Feedback from USF and follow-up at pharmacy, as per care protocol 1.7. Refill text reminder from pharmacy to patient (MED180®) 1.8. Quality Circles. Intervention is not likely to cause an adverse event. Yet, the intervention package at the pharmacy includes 1.9. reporting a suspected adverse event to the study team and to the National Pharmacovigilance System. 2. Control: Usual care.

Interventions

Inclusion criteria

1. Patients of selected USF 2. Age 18 years or older 3. On medication for hypertension and/or hyperlipidemia For technical reasons, intervention patients need to be holders of a NHS number, users of a mobile phone, registered in the NHS online portal Citizen Area, adherent to the National Association of Pharmacies (ANF) Pharmacy Loyalty Program Saúda®, with a Pharmacy Patient Medication Record.

Exclusion criteria

Diabetic patients

Locations

Related clinical trials

View on source registry